
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is well-positioned for growth in the personalized cancer treatment market with its cutting-edge technology, expanding Medicare coverage, strategic acquisitions, and partnerships. Their strong financial position and focus on profitability make them a promising investment opportunity with potential for long-term success.
Bears say
Personalis is facing uncertainties in securing Medicare coverage for its NeXT Personal MRD for pan-cancer immunotherapy (IO), which represents a potential large market opportunity. While Personalis has a strong IP estate and a collaboration agreement with TempusAI, it still faces competition and pricing challenges in its base NIPT and transplant businesses. Additionally, its reliance on large pharmaceutical companies and its diverse product offerings pose operational execution risks.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares